{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:32:16Z","timestamp":1768505536174,"version":"3.49.0"},"posted":{"date-parts":[[2023,3,15]]},"group-title":"Neuroscience","reference-count":55,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Inflammatory processes are activated following ischemic strokes and lead to increased tissue damage for weeks following the ischemic insult, but there are no approved therapies that target this inflammation-induced secondary injury. Here, we report that SynB1-ELP-p50i, a novel protein inhibitor of the nuclear factor kappa B (NF-\u03baB) inflammatory cascade bound to drug carrier elastin-like polypeptide (ELP), is able to enter both neurons and microglia, cross the blood-brain barrier, localize exclusively in the ischemic core and penumbra in Wistar-Kyoto and spontaneously hypertensive rats (SHRs), and reduce infarct volume in male SHRs. Additionally, in male SHRs, SynB1-ELP-p50i treatment improves survival for 14 days following stroke with no effects of toxicity or peripheral organ dysfunction. These results show high potential for ELP-delivered biologics for therapy of ischemic stroke and other central nervous system disorders and further support targeting inflammation in ischemic stroke.<\/jats:p>","DOI":"10.1101\/2023.03.15.532834","type":"posted-content","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T21:15:27Z","timestamp":1678914927000},"source":"Crossref","is-referenced-by-count":0,"title":["Elastin-like polypeptide delivery of anti-inflammatory peptides to the brain following ischemic stroke"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9875-6022","authenticated-orcid":false,"given":"John Aaron","family":"Howell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Gaouette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariper","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen P.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddie","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Gene L.","family":"Bidwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023032001250520000_2023.03.15.532834v1.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000558"},{"key":"2023032001250520000_2023.03.15.532834v1.2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S56071"},{"key":"2023032001250520000_2023.03.15.532834v1.3","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.122.036946"},{"key":"2023032001250520000_2023.03.15.532834v1.4","first-page":"7","volume":"333","author":"Tissue Plasminogen Activator for Acute Ischemic Stroke","year":"1995","journal-title":"The New England Journal of Medicine"},{"key":"2023032001250520000_2023.03.15.532834v1.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706442"},{"key":"2023032001250520000_2023.03.15.532834v1.6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/STROKEAHA.121.036948","article-title":"Neuroinflammation, Stem Cells, and Stroke","volume":"53","year":"2022","journal-title":"Stroke"},{"key":"2023032001250520000_2023.03.15.532834v1.7","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0483-x"},{"key":"2023032001250520000_2023.03.15.532834v1.8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neuron.2017.07.030","article-title":"The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease","volume":"96","year":"2017","journal-title":"Neuron"},{"key":"2023032001250520000_2023.03.15.532834v1.9","doi-asserted-by":"crossref","unstructured":"Jayaraj, R. L. , Azimullah, S. , Beiram, R. , Jalal, F. Y. & Rosenberg, G. A. Neuroinflammation: friend and foe for ischemic stroke. Journal of Neuroinflammation 16, (2019).","DOI":"10.1186\/s12974-019-1516-2"},{"key":"2023032001250520000_2023.03.15.532834v1.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-2938-1"},{"key":"2023032001250520000_2023.03.15.532834v1.11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4155\/tde-2019-0075","article-title":"Targeting the NF-\u03baB pathway for therapy of ischemic stroke","volume":"11","year":"2020","journal-title":"Therapeutic Delivery"},{"key":"2023032001250520000_2023.03.15.532834v1.12","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.2174\/138161212802002841","article-title":"Permeating the Blood Brain Barrier and Abrogating the Inflammation in Stroke: Implications for Stroke Therapy","volume":"18","year":"2012","journal-title":"Current Pharmaceutical Design"},{"key":"2023032001250520000_2023.03.15.532834v1.13","doi-asserted-by":"crossref","first-page":"1013311","DOI":"10.3389\/fimmu.2022.1013311","article-title":"Microglia autophagy in ischemic stroke: A double-edged sword","volume":"13","year":"2022","journal-title":"Front. Immunol"},{"key":"2023032001250520000_2023.03.15.532834v1.14","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.000780"},{"key":"2023032001250520000_2023.03.15.532834v1.15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1474-4422(16)30357-X","article-title":"Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial","volume":"16","year":"2017","journal-title":"The Lancet Neurology"},{"key":"2023032001250520000_2023.03.15.532834v1.16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1517\/17425240903143745","article-title":"Therapeutic peptides for cancer therapy. Part I \u2013 peptide inhibitors of signal transduction cascades","volume":"6","year":"2009","journal-title":"Expert Opinion on Drug Delivery"},{"key":"2023032001250520000_2023.03.15.532834v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2008.07.007"},{"key":"2023032001250520000_2023.03.15.532834v1.18","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvq076"},{"key":"2023032001250520000_2023.03.15.532834v1.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.22952"},{"key":"2023032001250520000_2023.03.15.532834v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/15100"},{"key":"2023032001250520000_2023.03.15.532834v1.21","doi-asserted-by":"crossref","unstructured":"Thomas, E. & Raucher, D. A thermally targeted carrier of p50 NLS peptide inhibits cancer cell proliferation by preventing NFkB nuclear translocation. in vol. 70 (Cancer Res, 2010).","DOI":"10.1158\/1538-7445.AM10-2659"},{"key":"2023032001250520000_2023.03.15.532834v1.22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/HYPERTENSIONAHA.119.13368","article-title":"Biopolymer-Delivered, Maternally Sequestered NF-\u03baB (Nuclear Factor-\u03baB) Inhibitory Peptide for Treatment of Preeclampsia","volume":"75","year":"2020","journal-title":"Hypertension"},{"key":"2023032001250520000_2023.03.15.532834v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2011.12.042"},{"key":"2023032001250520000_2023.03.15.532834v1.24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055104"},{"key":"2023032001250520000_2023.03.15.532834v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2010.05.003"},{"key":"2023032001250520000_2023.03.15.532834v1.26","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3390\/pharmaceutics14102072","article-title":"Elastin-like Polypeptide Hydrogels for Tunable, Sustained Local Chemotherapy in Malignant Glioma","volume":"14","year":"2022","journal-title":"Pharmaceutics"},{"key":"2023032001250520000_2023.03.15.532834v1.27","doi-asserted-by":"crossref","unstructured":"Liang, P. Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy. 10 (2021).","DOI":"10.1016\/j.biomaterials.2020.120447"},{"key":"2023032001250520000_2023.03.15.532834v1.28","doi-asserted-by":"crossref","first-page":"F411","DOI":"10.1152\/ajprenal.00158.2021","article-title":"Intrarenal modulation of NF-\u03baB activity attenuates cardiac injury in a swine model of CKD: a renal-cardio axis","volume":"321","year":"2021","journal-title":"American Journal of Physiology-Renal Physiology"},{"key":"2023032001250520000_2023.03.15.532834v1.29","doi-asserted-by":"publisher","DOI":"10.1124\/mol.57.4.679"},{"key":"2023032001250520000_2023.03.15.532834v1.30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2008.11.015","article-title":"Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides","volume":"135","year":"2009","journal-title":"Journal of Controlled Release"},{"key":"2023032001250520000_2023.03.15.532834v1.31","doi-asserted-by":"crossref","unstructured":"Kuna, M. , Mahdi, F. , Chade, A. R. & Bidwell, G. L. Molecular Size Modulates Pharmacokinetics, Biodistribution, and Renal Deposition of the Drug Delivery Biopolymer Elastin-like Polypeptide. Scientific Reports 8, (2018).","DOI":"10.1038\/s41598-018-24897-9"},{"key":"2023032001250520000_2023.03.15.532834v1.32","unstructured":"Thomas, E. Optimizing the delivery of therapeutic peptides using elastin-like polypeptide. (University of Mississippi Medical Center, 2010)."},{"key":"2023032001250520000_2023.03.15.532834v1.33","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5484.1550"},{"key":"2023032001250520000_2023.03.15.532834v1.34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311192200"},{"key":"2023032001250520000_2023.03.15.532834v1.35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M314278200"},{"key":"2023032001250520000_2023.03.15.532834v1.36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.24.14255"},{"key":"2023032001250520000_2023.03.15.532834v1.37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13221-014-0026-3","article-title":"Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis","volume":"7","year":"2015","journal-title":"Vascular Cell"},{"key":"2023032001250520000_2023.03.15.532834v1.38","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-04-0253"},{"key":"2023032001250520000_2023.03.15.532834v1.39","first-page":"84","article-title":"Reversible middle cerebral artery occlusion without craniectomy in rats","volume":"20","year":"1988","journal-title":"Stroke"},{"key":"2023032001250520000_2023.03.15.532834v1.40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148503"},{"key":"2023032001250520000_2023.03.15.532834v1.41","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.026652"},{"key":"2023032001250520000_2023.03.15.532834v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(96)00815-3"},{"key":"2023032001250520000_2023.03.15.532834v1.43","doi-asserted-by":"crossref","first-page":"605398","DOI":"10.3389\/fphys.2020.605398","article-title":"Blood-Brain Barrier Damage in Ischemic Stroke and Its Regulation by Endothelial Mechanotransduction","volume":"11","year":"2020","journal-title":"Front. Physiol"},{"key":"2023032001250520000_2023.03.15.532834v1.44","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00143.2016"},{"key":"2023032001250520000_2023.03.15.532834v1.45","doi-asserted-by":"publisher","DOI":"10.3791\/54987"},{"key":"2023032001250520000_2023.03.15.532834v1.46","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-012-9406-8"},{"key":"2023032001250520000_2023.03.15.532834v1.47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12974-018-1239-9","article-title":"The splenic response to stroke: from rodents to stroke subjects","volume":"15","year":"2018","journal-title":"J Neuroinflammation"},{"key":"2023032001250520000_2023.03.15.532834v1.48","doi-asserted-by":"crossref","first-page":"13101","DOI":"10.3390\/ijms222313101","article-title":"Neuroinflammation as a Key Driver of Secondary Neurodegeneration Following Stroke?","volume":"22","year":"2021","journal-title":"IJMS"},{"key":"2023032001250520000_2023.03.15.532834v1.49","doi-asserted-by":"crossref","first-page":"175628641878985","DOI":"10.1177\/1756286418789854","article-title":"Anti-inflammatory treatments for stroke: from bench to bedside","volume":"11","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"2023032001250520000_2023.03.15.532834v1.50","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1161\/HYPERTENSIONAHA.121.18602","article-title":"Mechanisms of Flow-Mediated Dilation of Pial Collaterals and the Effect of Hypertension","volume":"79","year":"2022","journal-title":"Hypertension"},{"key":"2023032001250520000_2023.03.15.532834v1.51","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2217\/fnl.14.44","article-title":"Animal models of stroke: translational potential at present and in 2050","volume":"9","year":"2014","journal-title":"Future Neurology"},{"key":"2023032001250520000_2023.03.15.532834v1.52","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.520304"},{"key":"2023032001250520000_2023.03.15.532834v1.53","doi-asserted-by":"crossref","first-page":"110686","DOI":"10.1016\/j.biopha.2020.110686","article-title":"Animal models of cerebral ischemia: A review","volume":"131","year":"2020","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2023032001250520000_2023.03.15.532834v1.54","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.2147\/DDDT.S106216","article-title":"Intranasal administration of elastin-like polypeptide for therapeutic delivery to the central nervous system","volume":"10","year":"2016","journal-title":"Drug Design, Development and Therapy"},{"key":"2023032001250520000_2023.03.15.532834v1.55","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1152\/physiol.00026.2021","article-title":"Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform","volume":"36","year":"2021","journal-title":"Physiology"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.03.15.532834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:24:38Z","timestamp":1768451078000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.03.15.532834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":55,"URL":"https:\/\/doi.org\/10.1101\/2023.03.15.532834","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1096\/fj.202300309RR","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,3,15]]},"subtype":"preprint"}}